Apollo Endosurgery

About:

Apollo Endosurgery develops medical devices for the diagnosis and treatment of gastrointestinal diseases.

Top Investors: H.I.G. Capital, Novo Holdings, MidCap Financial, CPMG, East West Bank

Description:

Apollo Endosurgery develops medical devices for the diagnosis and treatment of gastrointestinal diseases. The company’s device-based therapies are an alternative to invasive surgical procedures, thus lowering complication rates and reducing total healthcare costs. Apollo’s products include the X-Tack™ Endoscopic HeliX Tacking System, the OverStitch™ Endoscopic Suturing System, the OverStitch Sx™ Endoscopic Suturing System, and the ORBERA® Intragastric Balloon. Apollo Endosurgery was founded upon the initial work of the Apollo Group, an international think tank of world-renowned gastroenterologists and surgeons from five leading universities (Mayo Clinic, Johns Hopkins, Medical University of South Carolina, University of Texas Medical Branch-Galveston and Chinese University-Hong Kong.) Disappointed with the pace of innovation in therapeutic flexible endoscopy, the Group assembled in 1998 (Timeline) with the goal to advance the new discipline; their specific focus was the use of long, flexible instruments deployed through a natural orifice in order to diagnose and potentially treat gastrointestinal disorders.

Total Funding Amount:

$434M

Estimated Revenue Range:

$10M to $50M

Headquarters Location:

Austin, Texas, United States

Founded Date:

2006-01-01

Founders:

Dennis McWilliams

Number of Employees:

251-500